Share the post "Anchor Investor Transactions on 18 Sep – SUDARSHAN PHARMA INDUSTRIES"
Company | Client name | Buy/Sell | Qty Traded | Price | Trader | Trader Category |
---|---|---|---|---|---|---|
Navkar Urbanstructure | Moonlight Multitrade Llp | Sell | 1M | 14.53 | Setu Securities Pvt | public |
Navkar Urbanstructure | Dipakkumar Chimanlal Shah | Sell | 2M | 14.53 | Setu Securities Pvt | public |
Sudarshan Pharma Industries | Saroj Gupta | Buy | 150K | 331.81 | Mansi Share & Stock Advisors Private | public |
Sudarshan Pharma Industries | Saroj Gupta | Sell | 75K | 333.55 | Mansi Share & Stock Advisors Private | public |
The 1M shares of Navkar Urbanstructure have been sold by the Moonlight Multitrade Llp at a price of ₹14.53 per share and it is purchased by Setu Securities Pvt at a price of ₹14.53 per shares. The trader belongs to public category
The 2M shares of Navkar Urbanstructure have been sold by the Dipakkumar Chimanlal Shah at a price of ₹14.53 per share and it is purchased by Setu Securities Pvt at a price of ₹14.53 per shares. The trader belongs to public category
The 150K shares of Sudarshan Pharma Industries have been purchased by the Saroj Gupta at a price of ₹331.81 per share and it is sold by Mansi Share & Stock Advisors Private at a price of ₹331.81 per shares. The trader belongs to public category
The 75K shares of Sudarshan Pharma Industries have been sold by the Saroj Gupta at a price of ₹333.55 per share and it is purchased by Mansi Share & Stock Advisors Private at a price of ₹333.55 per shares. The trader belongs to public category
NAVKAR URBANSTRUCTURE LIMITED
0.00
Net Sales
20.51
Net Profit
39.81
Total Income
-19.30
Expenditure
12.6
Current Price
282
Market Cap
For NAVKAR URBANSTRUCTURE LIMITED, the latest financial data showcases impressive results. The company reported net sales of ₹0.00 million and total income of ₹39.81 million for the quarter. Expenditure was ₹-19.30 million, resulting in a net profit of ₹20.51 million. EPS for continuing operations was ₹0.09. Additional financial details include other income of ₹0.11 million, finance costs of ₹-0.42 million, and employee benefit expenses of ₹-1.03 million. Depreciation and amortization expenses were ₹0.00 million. Current tax was ₹0.00 million and deferred tax amounted to ₹0.00 million. Total comprehensive income for the period was ₹0.00 million, with other comprehensive income net of taxes at ₹0.00 million.
The company's market cap is ₹282 crore, with a stock price of ₹12.6. The historical stock range has been between ₹16.8 / 3.70. Its Price-to-Earnings (P/E) ratio of 274 indicates a high valuation. The book value per share is ₹7.01, and it has a dividend yield of 0.15%. The ROCE is 1.04% and ROE is 0.66%. With a very low debt-to-equity ratio of 0.09, the company is minimally leveraged. However, it reports a negative net cash flow of ₹4.87 crore. The Piotroski score of 7.00 and the Graham Number of ₹2.68 show mixed financial indicators, while the Price-to-Book (P/B) ratio of 1.80 suggests the stock is trading at a premium.